



INTERNATIONAL HEPATOLOGY EXCHANGE

Together, for patients

Friday 21 February 2020, 13.00–18.00

Saturday 22 February 2020, 08.30–13.30

NH Conference Hotel Noordwijk, Amsterdam, The Netherlands

INVITATION

On behalf of Gilead Sciences, we are delighted to invite you to attend the **International Hepatology Exchange** meeting, now in its **sixth** year.

The burden of liver disease is continuously evolving and presenting new challenges to the effective identification, management and long-term care of **patients**. As such, this year's meeting will explore important topics not only in **HCV, HBV** and **NASH**, but will also provide expert insights on **liver disease** due to other causes.

The expert international faculty will lead a highly interactive programme that will provide attendees with many opportunities to **discuss, debate** and **challenge** current **hot topics** across the liver disease spectrum and exchange practical experience in clinical scenarios that are encountered in daily practice. We hope this **experience exchange** format will arm you with valuable knowledge and insights that can help you to improve the care of your **patients** with liver disease.

Yours sincerely

Marjoleine L. Op den Brouw

Senior Director Medical Affairs HBV
Gilead Sciences Europe Ltd

Michael Mertens

Senior Director Medical Affairs HCV
Gilead Sciences Europe Ltd

Alan Smith

Senior Director Medical Affairs NASH
Gilead Sciences Europe Ltd

PROGRAMME

DAY 1: Friday 21 February 2020, 13.00–18.00

Welcome and Gilead's commitment to liver diseases	Michael Mertens (Gilead)
Introduction from the meeting Chair	Stefan Zeuzem (Germany)
SESSION 1: Patients with liver disease – how can we find them?	
Putting patients at the core of liver disease management	Stefan Zeuzem
How close are we to achieving HCV elimination?	Graham Foster (United Kingdom)
NASH pathways – finding patients and linking them to care	Salvador Augustin (Spain)
MULTIDISCIPLINARY PANEL NASH patients – whose role is it anyway? Making a difference in patients at risk	Chair: Salvador Augustin, Stefan Zeuzem Cardiovascular Physician: Neil Poulter (United Kingdom) Diabetologist: Tina Vilsbøll (Denmark) Hepatologist: Victor De Lédinghen (France) Gastroenterologist: Ulrich Beuers (The Netherlands)
DISCUSSION	Chair: Stefan Zeuzem Panel: Graham Foster, Salvador Augustin, Neil Poulter, Victor de Lédinghen, Tina Vilsbøll, Ulrich Beuers
Break	
SESSION 2: Patients with liver disease – how should we manage them?	
PLENARY Simplification of care – moving patient management outside the hepatology clinic	Alessandra Mangia (Italy), Anthony Martinez (USA)
WORKSHOPS Elimination is happening – peer exchange	
• HCV elimination – what is required to implement global policy at a local level?	José Luis Calleja (Spain)
• Practicalities and benefits of a test-and-treat approach	Victor de Lédinghen
• HCV micro-elimination in the prison setting	Stuart McPherson (United Kingdom)
• HCV patient management in the addiction setting	Anthony Martinez
• Success factors of a mobile outreach model of care	Graham Foster
Introduction to walking dinner with educational aspect and orientation for Day 2	
Dinner (to be served from 19.00)	

DAY 2: Saturday 22 February 2020, 08.30–13.30

Welcome back	Stefan Zeuzem
SESSION 2: Patients with liver disease – how should we manage them? (continued)	
PLENARY Hot topics in liver diseases <i>Alcoholic hepatitis, cholestatic liver disease, hepatocellular carcinoma, autoimmune hepatitis and more</i>	Chair: Stefan Zeuzem Stuart McPherson, Ulrich Beuers, Salvador Augustin, Tom Hemming Karlsen (Norway)
DISCUSSION Answers to your questions across the liver disease spectrum	Stefan Zeuzem, Graham Foster, Stuart McPherson, Ulrich Beuers, Salvador Augustin, Tom Hemming Karlsen
CASE-BASED WORKSHOPS Clinical best practice in liver disease	
• Management of liver disease during pregnancy	Maria Buti (Spain), Pietro Lampertico (Italy)
• Management of PSC and PBC	Ulrich Beuers, Tom Hemming Karlsen
• In the current DAA era, when is accurate fibrosis assessment still needed?	José Luis Calleja, Anthony Martinez
• Assessment and identification of high-risk patients with NASH	Victor de Lédinghen, Salvador Augustin
• Management of HCV DAA treatment failures	Stuart McPherson, Stefan Zeuzem
• Which HCV patients still need management in specialist care?	Alessandra Mangia, Graham Foster
Break	
CASE-BASED WORKSHOPS Clinical best-practice in liver disease (continued)	
• State-of-the-art management of HBV	Pietro Lampertico
• HBV management in a core-positive patient	Henry Chan (Hong Kong)
• Management of 'grey zone' HBV patients	Maria Buti
SESSION 3: Patients with liver disease – what about long-term follow-up?	
DEBATE Does choice of NA influence risk of HCC in CHB?	Chair: Maria Buti YES: Henry Chan NO: Pietro Lampertico
PLENARY Together, for patients – the future in liver care	Tom Hemming Karlsen, Henry Chan
Meeting close	Stefan Zeuzem, Kim Vanstraelen (Gilead)
Lunch	

